The Brain Imaging Research Core, BIRC, a new core in this Center, has assembled a group of highly skilled investigators with expertise in various aspects of brain imaging such as study design, image analysis, radiochemistry and kinetic modeling. The general missions of the BIRC will include: 1) providing expert logistical support to """"""""project specific"""""""" studies, 2) training young investigators, 3) providing """"""""center wide"""""""" measurements (MRI volumetric analyses and electrophysiological studies), and 4) development new imaging modalities pertinent to schizophrenia.. """"""""Project specific"""""""" studies are generally performed on a predefined set of patients, and are mainly funded by RO1s while """"""""center- wide"""""""" measurements are performed on all patients admitted to the Center and are available to all investigators of the MHCRC. Over the next five years, the development effort of this core will target the dopamine (DA) system with PET, and the gamma-amino-butyric (GABA) system with MRS. The choice of these objectives is guided by a general model of neurochemical imbalances and dysregulations in specific cortico-subcortical neuronal networks in schizophrenia. The overall hypothesis, based on preliminary results and data from animal models, proposes that schizophrenia is related to a failure of normal brain development associated with disruption of hippocampal formation connectivity, and reduction of DA and/or GABA function in the prefrontal cortex (PFC), leading to a dysregulation of subcortical DA systems. We will develop and validate measures of DA activity in the PFC in schizophrenia, using a D1 receptor radiotracer, [11C]NNC 112, and a DA depletion paradigm, and in the mesial temporal structures using a high affinity D2 receptor radiotracer, [18F]fallypride, combined with DA challenge tests. We will develop a D2 receptor agonist, [11C] pramipexole, to study potential alterations in the affinity of D2 receptors for agonists in schizophrenia; and a radiotracer for the D4 receptor, [18F]fluoropropyl-L745,870. For the GABAergic system, our goal is to develop and validate an MRS method to measure GABA concentration in the PFC in schizophrenia. Combined together, these developments will provide the tools to test different components of the cortico-subcortical network in schizophrenia, and to integrate them into a heuristic model of the illness.

Agency
National Institute of Health (NIH)
Institute
National Institute of Mental Health (NIMH)
Type
Center Core Grants (P30)
Project #
5P30MH059342-03
Application #
6495757
Study Section
Clinical Centers and Special Projects Review Committee (CCSP)
Project Start
2001-09-01
Project End
2002-12-31
Budget Start
Budget End
Support Year
3
Fiscal Year
2001
Total Cost
$73,467
Indirect Cost
Name
New York State Psychiatric Institute
Department
Type
DUNS #
167204994
City
New York
State
NY
Country
United States
Zip Code
10032
Goetz, Raymond R; Corcoran, Cheryl; Yale, Scott et al. (2007) Validity of a 'proxy'for the deficit syndrome derived from the Positive And Negative Syndrome Scale (PANSS). Schizophr Res 93:169-77
Kimhy, David; Yale, Scott; Goetz, Raymond R et al. (2006) The factorial structure of the schedule for the deficit syndrome in schizophrenia. Schizophr Bull 32:274-8
Kayser, Jurgen; Tenke, Craig E (2006) Principal components analysis of Laplacian waveforms as a generic method for identifying ERP generator patterns: I. Evaluation with auditory oddball tasks. Clin Neurophysiol 117:348-68
Kayser, Jurgen; Tenke, Craig E (2006) Principal components analysis of Laplacian waveforms as a generic method for identifying ERP generator patterns: II. Adequacy of low-density estimates. Clin Neurophysiol 117:369-80
van Berckel, Bart N M; Kegeles, Lawrence S; Waterhouse, Rikki et al. (2006) Modulation of amphetamine-induced dopamine release by group II metabotropic glutamate receptor agonist LY354740 in non-human primates studied with positron emission tomography. Neuropsychopharmacology 31:967-77
Slifstein, Mark; Narendran, Raj; Hwang, Dah-Ren et al. (2004) Effect of amphetamine on [(18)F]fallypride in vivo binding to D(2) receptors in striatal and extrastriatal regions of the primate brain: Single bolus and bolus plus constant infusion studies. Synapse 54:46-63
Slifstein, Mark; Hwang, Dah-Ren; Huang, Yiyun et al. (2004) In vivo affinity of [18F]fallypride for striatal and extrastriatal dopamine D2 receptors in nonhuman primates. Psychopharmacology (Berl) 175:274-86
Waterhouse, Rikki N; Slifstein, Mark; Dumont, Filip et al. (2004) In vivo evaluation of [11C]N-(2-chloro-5-thiomethylphenyl)-N'-(3-methoxy-phenyl)-N'-methylguanidine ([11C]GMOM) as a potential PET radiotracer for the PCP/NMDA receptor. Nucl Med Biol 31:939-48
Huang, Yiyun; Hwang, Dah-Ren; Bae, Sung-A et al. (2004) A new positron emission tomography imaging agent for the serotonin transporter: synthesis, pharmacological characterization, and kinetic analysis of [11C]2-[2-(dimethylaminomethyl)phenylthio]-5-fluoromethylphenylamine ([11C]AFM). Nucl Med Biol 31:543-56
Harkavy-Friedman, Jill M; Nelson, Elizabeth A; Venarde, David F et al. (2004) Suicidal behavior in schizophrenia and schizoaffective disorder: examining the role of depression. Suicide Life Threat Behav 34:66-76

Showing the most recent 10 out of 30 publications